Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 6 more changesShow less
    • Primary completion date changed from estimate of Oct 1, 2027 to Aug 17, 2026
    • Study completion moved earlier from Oct 1, 2028 to Feb 17, 2027
    • Start date: Apr 1, 2022 to Apr 25, 2022
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Secondary endpoints: 3 to 5v14
  3. Primary completion date: Mar 1, 2026 to Oct 1, 2027
    • Study completion date: Mar 1, 2026 to Oct 1, 2028
    v13
  4. Primary completion date: Mar 2025 to Mar 1, 2026
    • Study completion date: Mar 2026 to Mar 1, 2026
    v12
  5. Primary endpoint revised
    • Secondary endpoints revised (3)
    • Study site revised
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Re-verified, no change to tracked fieldsv10
  2. Site contact updatedv9
  3. Primary completion date: Apr 15, 2024 to Mar 2025
    • Study completion date: Apr 15, 2025 to Mar 2026
    v8
  4. Re-verified, no change to tracked fieldsv7
  5. Lead sponsor: University of Arizona to Mayo Clinicv6 Show 6 more changesShow less
    • Trial status: Withdrawn to Recruiting
    • Primary completion date: Feb 23, 2021 to Apr 15, 2024
    • Start date: Dec 17, 2020 to Apr 1, 2022
    • Enrollment target: 0 to 40
    • Study completion date: Mar 23, 2021 to Apr 15, 2025
    • Study site revised
  6. Trial status: Recruiting to Withdrawn Sponsor's reason: PI leaving institution; closing trial and reopening at another site; no accruals.v5 Show 4 more changesShow less
    • Enrollment target: estimated 40 to confirmed 0
    • Primary completion date changed from estimate of Jun 1, 2023 to Feb 23, 2021
    • Study completion date: Jun 1, 2023 to Mar 23, 2021
    • Site details revised
  7. Eligibility criteria revisedv4
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2020 to Dec 17, 2020
    v3
  9. Study title revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,024 trials monitored
See 128 trials at risk
Pancreatic Cancer
1,740 trials monitored
See 105 trials at risk
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.
Trial Details
NCT Number NCT04605913
Lead Sponsor Mayo Clinic
Collaborators: NovoCure Ltd.
Conditions
(from sponsor)		 Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
Related terms Adenocarcinoma, Pancreatic Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov